4//SEC Filing
ZANTE GREG 4
Accession 0000950170-25-002485
CIK 0001607678other
Filed
Jan 5, 7:00 PM ET
Accepted
Jan 6, 8:14 PM ET
Size
13.2 KB
Accession
0000950170-25-002485
Insider Transaction Report
Form 4
ZANTE GREG
Chief Financial Officer
Transactions
- Award
Common Stock, par value $0.00001 per share
2025-01-03+21,667→ 215,568 total - Sale
Common Stock, par value $0.00001 per share
2025-01-06$42.69/sh−45,609$1,946,993→ 169,959 total - Sale
Common Stock, par value $0.00001 per share
2025-01-06$43.32/sh−4,700$203,601→ 165,259 total - Award
Common Stock, par value $0.00001 per share
2025-01-03+44,533→ 193,901 total - Award
Stock Option (Right to Buy)
2025-01-03+37,200→ 37,200 totalExercise: $42.89From: 2026-01-03Exp: 2035-01-03→ Common Stock (37,200 underlying)
Footnotes (7)
- [F1]Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award.
- [F2]Includes 2 shares acquired on November 20, 2024 pursuant to the Issuer's 2024 Employee Stock Purchase Plan.
- [F3]The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2024, 33.33% of which vested on January 3, 2025 upon the achievement of a non-financial performance goal.
- [F4]These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards and certain performance restricted stock unit awards.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.19 to $43.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.20 to $43.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F7]25% of the shares subject to the option will vest on each anniversary of the grant date.
Documents
Issuer
Viking Therapeutics, Inc.
CIK 0001607678
Entity typeother
Related Parties
1- filerCIK 0001264949
Filing Metadata
- Form type
- 4
- Filed
- Jan 5, 7:00 PM ET
- Accepted
- Jan 6, 8:14 PM ET
- Size
- 13.2 KB